Immunicon to Chair Pre-Conference Course on Circulating Tumor Cells as Biomarkers at Molecular Medicine Tri-Conference

Leon W.M.M. Terstappen, MD, Ph.D., Chief Scientific Officer of Immunicon Corporation (NASDAQ-GM:IMMC) will chair a pre-conference short course at the Cambridge Healthtech Institute’s Molecular Medicine Tri-Conference 9:00 a.m. to noon, Tuesday, February 27 at the Moscone North Convention Center in San Francisco. The presentations will address circulating tumor cells (CTCs) as a biomarker in cancer drug research and development. Byron D. Hewett, President and Chief Executive Officer of Immunicon, commented: "Some of the biggest names in the pharmaceutical industry are now working with Immunicon Pharma Services. We are pleased that CHI invited us to organize this pre-conference workshop so that experts from the FDA, academia and the pharmaceutical industry can share their experiences and information on the use of circulating tumor cells as biomarkers in clinical trials. Elevated CTCs have been shown to predict survival in patients with metastatic breast cancer and can be used to monitor patients during their treatment. We believe that CTCs can offer efficacy information in the context of a clinical trial earlier than traditional means, such as CT scans, which may make trials more efficient and ultimately get good drugs to market sooner.” Terstappen will chair the pre-conference short course (SC5), "Circulating Tumor Cells (CTCs) as Biomarkers and their use in Oncology Clinical Trial Design.” The agenda includes: 9:00 a.m. FDA-CDER Current Biomarker Qualification Process Map Federico M. Goodsaid, Ph.D., Genomics Group Office of Translational Science, FDA-CDER 9:30 a.m. Understanding of the Biology, Origin and Clinical Significance of CTCs John W. Park, M.D., Associate Professor, Medicine, University of California, San Francisco 10:00 a.m. Coffee Break 10:15 a.m. The Preclinical & Clinical Development of the CellSearch(TM) Assay: Its Specifications and Clinical Relevance Leon Terstappen, M.D., Ph.D., Senior Vice President and Chief Scientific Officer of R&D, Immunicon 10:45 a.m. Overview of Completed & Ongoing Prospective Clinical Trials that Employ CTCs Gerald V. Doyle, DDS, MS, Senior Director, Clinical Research, Immunicon 11:15 a.m. Incorporation of CTCs in Phase I/II Clinical Trials of Novel Anti-Cancer Agents David R. Shalinsky, Ph.D., Associate Director, Translational Medicine, Pfizer Global Research and Development, La Jolla In addition, conference and course attendees are invited to a networking reception with the speakers and fellow attendees at 6:00 p.m. Wednesday, February 28 at the Corinthia Room of the Parc 55 Hotel. Refreshments will be provided. The Immunicon Pharma Services team offers assay development and clinical trial testing services to enhance the biomarker development and clinical programs of pharmaceutical and biotechnology companies. Immunicon currently has a number of agreements with pharmaceutical companies to use CTCs and circulating endothelial cells (CECs) as biomarkers in the development of therapeutic compounds. The CellSearch™ Circulating Tumor Cell Kit captures, counts and characterizes CTCs from a blood test. The kit was developed by Immunicon and is marketed by Veridex, LLC, a Johnson & Johnson company. For more about the Molecular Medicine Tri-Conference, visit http://www.tri-conference.com. About Immunicon Corporation Immunicon Corporation is developing and commercializing proprietary cell- and molecular-based human diagnostic and life science research products, and is providing certain analytical services to pharmaceutical and biotechnology companies to assist them in developing new therapeutic agents, with an initial focus on cancer disease management. Immunicon has developed platform technologies to identify, count and characterize a small number of rare cells in blood, such as circulating tumor cells and circulating endothelial cells that are important in many diseases and biological processes. Immunicon’s products and underlying technology platforms also have application in cancer research and may have applications in other fields of medicine, such as cardiovascular and infectious diseases. For more information, please visit www.immunicon.com. Forward-Looking Statements The information contained in this press release includes "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often preceded by words such as "hope,” "may,” "believe,” "anticipate,” "plan,” "expect,” "intend,” "assume,” "will” and similar expressions. Forward-looking statements contained in this press release include, among others, statements relating to key product, services and clinical development programs, the anticipated clinical utility of Immunicon’s products and services and other statements not of historical fact. Immunicon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date of this press release, reflect management’s current expectations and involve certain factors, such as risks and uncertainties that may cause actual results to be far different from those suggested by Immunicon’s forward-looking statements. These factors include, but are not limited to, risks and uncertainties associated with: Immunicon’s dependence on Veridex, LLC, a Johnson & Johnson company, in the field of cancer cell analysis; Immunicon’s capital and financing needs; research and development and clinical trial expenditures; commercialization of Immunicon’s product candidates; Immunicon’s ability to use licensed products and to obtain new licenses from third parties; Immunicon’s ability to manage its growth; obtaining necessary regulatory approvals; reliance on third party manufacturers and suppliers; reimbursement by third party payors to Immunicon’s customers for Immunicon’s products; compliance with applicable manufacturing standards; the ability to earn license and milestone payments under Immunicon’s agreement with Veridex; retaining key management or scientific personnel; delays in the development of new products or to planned improvements to Immunicon’s products; effectiveness of Immunicon’s products compared to competitors’ products; protection of Immunicon’s intellectual property and other proprietary rights; conflicts with the intellectual property of third parties; product liability lawsuits that may be brought against Immunicon; labor, contract or technical difficulties; and competitive pressures in Immunicon’s industry. These factors are discussed in more detail in Immunicon’s filings with the Securities and Exchange Commission. "Immunicon” and the Immunicon Corporation logo are registered trademarks of Immunicon Corporation. ”CellSearch” is a trademark of Johnson & Johnson. ALL RIGHTS RESERVED.